Literature DB >> 18756362

Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors.

Kazuhiro Kitajima1, Yuji Nakamoto, Hiromi Okizuka, Yumiko Onishi, Michio Senda, Narufumi Suganuma, Kazuro Sugimura.   

Abstract

OBJECTIVE: Positron emission tomography (PET) using (18)F-fluoro-2-deoxy-D -glucose (FDG) has a limitation in detecting cerebral metastases; however, the feasibility of detection by inline PET/computed tomography (CT) system remains unknown. We evaluated the accuracy of FDG-PET/CT of body imaging protocol for the detection of cerebral metastases when compared with PET alone and CT alone.
METHODS: Fifty patients underwent whole-body FDG-PET/CT scanning including the brain and contrast enhanced brain MR (magnetic resonance) scan. PET-only, CT-only, and the fused images were interpreted, and the confidence of presence of cerebral metastases was recorded using a five-point grading scale. Area under the receiver-operating characteristic (ROC) curve (Az) was calculated. Differences among the three modalities were tested with the Cochran-Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment.
RESULTS: Magnetic resonance imaging revealed 70 cerebral metastatic lesions in 20 patients. Patient-based analysis showed that the sensitivity, specificity, accuracy, and Az of PET-alone interpretation were 45%, 80%, 66%, and 0.6025, respectively, those of CT-alone interpretation were 50%, 97%, 78%, and 0.7158, respectively, and those of fused-image interpretation were 50%, 93%, 76%, and 0.7242, respectively. ROC analysis revealed significant differences among the three interpretation methods (P = 0.0238) and between PET and PET/CT (P = 0.0129). The sensitivity of PET, CT, and fused-image interpretation for detecting 70 lesions was 13%, 20%, and 20%, respectively.
CONCLUSIONS: Even with an integrated PET/CT scanner of body imaging protocol, the sensitivity of cerebral metastases remained unsatisfactory. To assess intracranial lesions, MR scanning should still be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756362     DOI: 10.1007/s12149-008-0145-0

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  16 in total

1.  Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer.

Authors:  Bekir Tasdemir; Zuhat Urakci; Zeki Dostbil; Kemal Unal; F Selcuk Simsek; Fatma Teke; Cemil Goya
Journal:  Radiol Med       Date:  2015-11-05       Impact factor: 3.469

2.  Added Value of Contrast Medium in Whole-Body Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Comparison between Contrast-Enhanced and Non-Contrast-Enhanced Protocols.

Authors:  Filiz Celebi; Emetullah Cindil; Dauren Sarsenov; Bulent Unalan; Cem Balcı
Journal:  Med Princ Pract       Date:  2019-06-17       Impact factor: 1.927

3.  Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain.

Authors:  Jinyu Chen; Ho-Jeong Lee; Xuefeng Wu; Lei Huo; Sun-Jin Kim; Lei Xu; Yan Wang; Junqing He; Lakshmi R Bollu; Guang Gao; Fei Su; James Briggs; Xiaojing Liu; Tamar Melman; John M Asara; Isaiah J Fidler; Lewis C Cantley; Jason W Locasale; Zhang Weihua
Journal:  Cancer Res       Date:  2014-12-15       Impact factor: 12.701

4.  Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.

Authors:  Amy N Melsaether; Roy A Raad; Akshat C Pujara; Fabio D Ponzo; Kristine M Pysarenko; Komal Jhaveri; James S Babb; Eric E Sigmund; Sungheon G Kim; Linda A Moy
Journal:  Radiology       Date:  2016-03-29       Impact factor: 11.105

5.  Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography.

Authors:  Robert R Flavell; Charles Truillet; Melanie K Regan; Tanushree Ganguly; Joseph E Blecha; John Kurhanewicz; Henry F VanBrocklin; Kayvan R Keshari; Christopher J Chang; Michael J Evans; David M Wilson
Journal:  Bioconjug Chem       Date:  2015-12-22       Impact factor: 4.774

Review 6.  Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know.

Authors:  Gensuke Akaike; Tomoko Akaike; Shaimaa A Fadl; Kristina Lachance; Paul Nghiem; Fatemeh Behnia
Journal:  Radiographics       Date:  2019 Nov-Dec       Impact factor: 6.312

Review 7.  PET/MRI in Oncological Imaging: State of the Art.

Authors:  Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook
Journal:  Diagnostics (Basel)       Date:  2015-07-21

8.  Evaluation of clinical contributions provided by addition of the brain, calvarium, and scalp to the limited whole body imaging area in FDG-PET/CT tumor imaging.

Authors:  Bekir Tasdemir; Zeki Dostbil; Ali Inal; Kemal Unal; Sule Yildirim; F Selcuk Simsek
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

9.  Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?

Authors:  B Salvatore; M G Caprio; R Fonti; D D'Amico; F Fraioli; M Salvatore; L Pace
Journal:  Transl Med UniSa       Date:  2014-12-19

Review 10.  Cerebral Gluconeogenesis and Diseases.

Authors:  James Yip; Xiaokun Geng; Jiamei Shen; Yuchuan Ding
Journal:  Front Pharmacol       Date:  2017-01-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.